Matinas BioPharma (NYSEAMERICAN:MTNB) Announces Earnings Results, Hits Estimates

Matinas BioPharma (NYSEAMERICAN:MTNB) issued its earnings results on Wednesday. The company reported ($0.02) EPS for the quarter, hitting the consensus estimate of ($0.02), Zacks reports.

Matinas BioPharma Stock Performance

NYSEAMERICAN MTNB remained flat at $0.15 during trading on Thursday. The company’s stock had a trading volume of 686,970 shares, compared to its average volume of 1,147,369. Matinas BioPharma has a 12-month low of $0.12 and a 12-month high of $0.89. The firm has a market capitalization of $38.38 million, a P/E ratio of -1.28 and a beta of 1.70.

Matinas BioPharma Company Profile

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.